2026 Asset Growth: Why Federal Compliance Is the New Metric

Executive Summary

• Doseology Sciences announced a strategic regulatory partnership with McKinney Regulatory Science Advisors to accelerate FDA‑related product development.
• Canopy Growth entered a definitive arrangement agreement to acquire all outstanding shares of MTL Cannabis Corp., valuing the deal at ~ $125 M (equity) / $179 M (enterprise).
• Keurig Dr Pepper launched a public cash offer to acquire JDE Peet’s N.V. at €31.85 per share, with closing expected early Q2 2026.

Key Details

• Doseology – Regulatory Partnership
• Announced Jan 9 2026; partnership with McKinney Regulatory Science Advisors (FDA regulatory consulting firm).
• Scope: formulation strategy, data generation, PMTA preparation, post‑market compliance, labeling & packaging, pre‑submission engagement plans.

• Intended outcome: expedite FDA approvals for oral nicotine/stimulant pouch products and strengthen IP protection.

• Canopy Growth – Acquisition of MTL Cannabis Corp.

• Transaction type: definitive arrangement agreement (share purchase).
• Consideration: each MTL shareholder receives 0.32 Canopy share + $0.144 cash per MTL share.
• Valuation: ≈ $125 M on a fully‑diluted equity basis; ≈ $179 M enterprise value.
• Expected synergies: ~$10 M run‑rate within 18 months.
• Approval required: ≥ 2/3 of MTL shareholder votes at special meeting (expected Q1 2026).

• Closing target: before end of Feb 2026, subject to TSX and Competition Act Canada approvals.

• Keurig Dr Pepper – Offer for JDE Peet’s N.V.

• Public cash offer: €31.85 per share.
• Offer memorandum approved by Dutch authorities; board of JDE Peet’s unanimously supports.
• Tender period: Jan 16 – Mar 27 2026; ~69% of shareholders (incl. Acorn Holdings B.V.) have irrevocably committed to tender.
• Post‑closing plan: split KDP into two independent U.S.-listed companies – a North American refreshment challenger and a global coffee leader.

• Closing expected early Q2 2026, contingent on ≥ 95% acceptance (or 80% with shareholder‑approved restructuring).

• Definium Therapeutics – Clinical Milestones

• Rebranded from Mind Medicine; ticker changed to DFTX effective Jan 13 2026.
• Phase 3 pipeline: four trials for DT120 ODT (FDA Breakthrough Therapy Designation for GAD).

• Upcoming readouts in 2026: Voyage study (GAD) Q2, Panorama (GAD) H2, Emerge (MDD) mid‑year, Ascend (MDD) mid‑year.

• Lipocine – Phase 3 Trial Safety Update

• DSMB review of LPCN 1154 for postpartum depression: trial to continue unchanged; 82 participants, no serious safety issues.
• Enrollment closed to new subjects; ongoing follow‑up for existing participants.
• Topline safety/efficacy results expected early Q2 2026; NDA filing planned later in 2026.

Notable Quotes

• “Doseology is committed to leading with science and innovation in the oral pouch category,” – Tim Corkum, President & COO, Doseology Sciences.
• “MTL brings skilled operators… strengthens our leadership in Canada’s medical market,” – Luc Mongeau, CEO, Canopy Growth.
• “The data generated to date reinforces our confidence in the safety profile of LPCN 1154,” – Mahesh Patel, CEO, Lipocine.